FNY Managed Accounts LLC increased its stake in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 73.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 52,000 shares of the company’s stock after buying an additional 22,000 shares during the period. FNY Managed Accounts LLC’s holdings in Aralez Pharmaceuticals were worth $172,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in ARLZ. Bank of Montreal Can bought a new stake in Aralez Pharmaceuticals during the second quarter valued at approximately $100,000. Goldman Sachs Group Inc. acquired a new position in shares of Aralez Pharmaceuticals during the first quarter valued at $109,000. Geode Capital Management LLC acquired a new position in shares of Aralez Pharmaceuticals during the first quarter valued at $273,000. Integre Asset Management LLC acquired a new position in shares of Aralez Pharmaceuticals during the first quarter valued at $291,000. Finally, Alps Advisors Inc. raised its position in shares of Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock valued at $297,000 after buying an additional 17,920 shares in the last quarter. 49.63% of the stock is currently owned by institutional investors and hedge funds.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 0.61% during midday trading on Wednesday, reaching $4.91. 468,949 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $5.23 and its 200 day moving average price is $4.13. Aralez Pharmaceuticals Inc. has a 1-year low of $3.10 and a 1-year high of $8.59. The firm’s market cap is $320.33 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.08. The business had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. Aralez Pharmaceuticals’s revenue was up 142.3% compared to the same quarter last year. Equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.05) EPS for the current year.
Several equities analysts recently weighed in on ARLZ shares. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Aralez Pharmaceuticals in a report on Sunday, August 14th. Guggenheim restated a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a report on Monday, August 15th.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the transaction, the director now directly owns 669,094 shares of the company’s stock, valued at $3,894,127.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.77% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.